[{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection, Extended Release","sponsorNew":"H. Lundbeck AS \/ Otsuka Holdings","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Holdings"},{"orgOrder":0,"company":"University of Miami","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Miami \/ Alkermes Plc","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Alkermes Plc"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Alkermes Plc \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor | Dopamine D2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Aripiprazole Lauroxil

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Aripiprazole Lauroxil

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

12 API Suppliers, 4 USDMF, 2 EU WC, 9 NDC API, 6 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

9 Drugs in Development

9 Drugs in Development

FINISHED DOSAGE FORMULATIONS

9 FDF Dossiers, 5 FDA Orange Book, 4 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 1064MG/3.9ML (272.82MG/ML), SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 441MG/1.6ML (275.63MG/ML), SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 662MG/2.4ML (275.83MG/ML), SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 882MG/3.2ML (275.63MG/ML), SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 675MG/2.4ML (281.25MG/ML)

RELATED EXCIPIENT COMPANIES

2 Nanjing Well Pharmaceutical, 3 Kirsch Pharma, 2 Actylis, 1 BASF, 1 Gangwal Chemicals, 1 Microlex e.U, 4 Seppic

EXCIPIENTS BY APPLICATIONS

8 Parenteral, 6 Solubilizers, 5 Surfactant & Foaming Agents, 4 Topical, 4 Emulsifying Agents, 2 Thickeners and Stabilizers, 1 Film Formers & Plasticizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 10 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

2 US Medicaid Prescriptions

MARKET PLACE

2 APIs

2 APIs

PATENTS & EXCLUSIVITIES

71 US Patents

71 US Patents

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

H. Lundbeck AS

Denmark

Peptide Process CMC

Not Confirmed

02

University of Miami

Country

Peptide Process CMC

Not Confirmed

03

Alkermes Plc

Ireland

Peptide Process CMC

Not Confirmed

04

Octapharma

Switzerland

Peptide Process CMC

Not Confirmed

05

University of California, Los Angeles

Country

Peptide Process CMC

Not Confirmed

06

Alkermes Plc

Ireland

Peptide Process CMC

Not Confirmed

07

Alkermes Plc

Ireland

Peptide Process CMC

Not Confirmed

08

Alkermes Plc

Ireland

Peptide Process CMC

Not Confirmed

09

Alkermes Plc

Ireland

Peptide Process CMC

Not Confirmed